ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Alexion to buy biopharmaceutical firm Portola in $1.41bn deal
May 06, 2020Alexion Pharmaceuticals has signed an agreement to acquire commercial-stage biopharmaceutical company Portola in a deal valued at around $1.41bn. -
Wham! Alexion investors sucker-punched as PTO takes up Amgen's Soliris patent challenge
September 02, 2019Alexion Pharmaceuticals investors were celebrating last week when word on the street said Amgen might buy out the company, but a week later, their mood is much different. -
Alexion Pharmaceuticals to File for FDA Approval of Soliris Successor in Mid-2018
April 28, 2018Alexion Pharmaceuticals closed out its first quarter plans to seek regulatory approval for its paroxysmal nocturnal hemoglobinuria (PNH) treatment, ALXN1210 -
EU Commission Grants New Indication for Soliris for Refractory gMG
August 23, 2017Alexion Pharmaceuticals announced the European Commission (EC) approved the extension of the indication for Soliris (eculizumab) to include the treatment of refractory generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR
Pharma Sources Insight January 2025
